Granulosa and thecal cells were isolated from 2 human ovarian follicles and the separated and recombined cells were incubated in vitro with acetate-l-14 C. Radioactively labeled cholesterol, pregnenolone, progesterone, 17-hydroxyprogesterone, androstenedione and estrone were isolated in radiochemically pure form from each of the experimental situations utilizing either granulosa, theca or a mixture of the 2 cell types. In addition, labeled dehydroepiandrosterone was isolated only from the incubation with granulosa cells, while labeled estradiol-17/3 was isolated only from the thecal cell and recombined studies. (J Clin Endocr 28: 355, 1968)

No abstract

Ovarian tissue from a 38 year old woman was incubated with and without FSH-* and LH-preparations from human pituitary glands. Both preparations stimulated the conversion of labelled androstenedione to oestrone and 17β-oestradiol. In both cases this effect was blocked by addition to the incubation medium of serum from rabbits immunized against HCG.

Transition from the hospital into the outpatient setting is a critical event for the appropriate provision of VTE prophylaxis. Data for this transition for the situation in Germany is scant. This was a retrospective, observational study in patients receiving in-hospital thromboprophylaxis and discharged with or without a recommendation to continue. Patient with previous thromboembolism were excluded. A total of 3,211 patients were identified by 518 physicians of which 2,853 had all data available for the present analysis; mean patient's age was 57.4 ± 17.5 (SD) years, 48.2% were male and bodyweight was 79.8 ± 16.1 kg. During hospitalization 95.5% of surgical and 84.0% of medical patients received any thromboprophylaxis, the mean hospital duration being 12.7 ± 20.3 days. Surgical patients had high, medium and low risk in 53.8, 37.1 and 9.1%, respectively. Medical patients had high, medium and low risk in 78.8, 19.8 and 1.4%. A hospital recommendation to continue thromboprophylaxis was given to 84.6% (95% CI 83.1-85.9%) of surgical and 64.9% (95% CI 59.1-70.6%) of medical patients and implemented in 96.6 and 94.3%, respectively. On the other hand, in patients without a respective hospital recommendation (15.4% of surgical and 35.1% of medical patients), thromboprophylaxis was continued in 65.3% of surgical and 73.1% of medical patients because of high risk. Our data illustrate acceptable rates of prophylaxis in surgical and medical patients in Germany. As the results show, it is essential that not only hospital physicians are aware of the actual risk at discharge, but office based physicians assess thromboembolic risk.